{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:14:35Z","timestamp":1778897675169,"version":"3.51.4"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006209","name":"Radboud Universitair Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006209","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.rpth.2025.103334","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T16:28:22Z","timestamp":1767025702000},"page":"103334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Direct oral anticoagulant interference and removal in the factor VIII inhibitor assay"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3992-3941","authenticated-orcid":false,"given":"Rick","family":"Timmerije","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia E.M.","family":"Schols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dani\u00eblle","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wideke","family":"Barteling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An K.","family":"Stroobants","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1593-424X","authenticated-orcid":false,"given":"Sanna R.","family":"Rijpma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.103334_bib1","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.3390\/jcm14092914","article-title":"Challenges and opportunities of direct oral anticoagulant (DOAC) therapy in complex clinical scenarios: a comprehensive review and practical guide","volume":"14","author":"Miceli","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.rpth.2025.103334_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/hematology.2021000241","article-title":"Direct oral anticoagulant (DOAC) interference in hemostasis assays","volume":"2021","author":"Moser","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.rpth.2025.103334_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.thromres.2015.05.001","article-title":"Direct oral anticoagulants (DOACs) in the laboratory: 2015 review","volume":"136","author":"Adcock","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.103334_bib4","first-page":"491","article-title":"Interference of direct oral anticoagulants in haemostasis assays: high potential for diagnostic false positives and false negatives","volume":"15","author":"Favaloro","year":"2017","journal-title":"Blood Transfus"},{"key":"10.1016\/j.rpth.2025.103334_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/ijlh.12992","article-title":"An update on laboratory assessment for direct oral anticoagulants (DOACs)","volume":"41","author":"Gosselin","year":"2019","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.rpth.2025.103334_bib6","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/hae.13930","article-title":"Reducing the effect of DOAC interference in laboratory testing for factor VIII and factor IX: a comparative study using DOAC Stop and andexanet alfa to neutralize rivaroxaban effects","volume":"26","author":"Favaloro","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103334_bib7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pathol.2015.11.025","article-title":"The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples","volume":"48","author":"Bonar","year":"2016","journal-title":"Pathology"},{"key":"10.1016\/j.rpth.2025.103334_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103334_bib9","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/jth.14488","article-title":"Resolving DOAC interference on aPTT, PT, and lupus anticoagulant testing by the use of activated carbon","volume":"17","author":"Frans","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103334_bib10","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1055\/s-0038-1657785","article-title":"Evaluation of the DOAC-Stop\u00ae procedure to overcome the effect of DOACs on several thrombophilia screening tests","volume":"2","author":"Favresse","year":"2018","journal-title":"TH Open"},{"key":"10.1016\/j.rpth.2025.103334_bib11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0038-1653759","article-title":"The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability","volume":"73","author":"Verbruggen","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103334_bib12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.thromres.2023.10.007","article-title":"The Nijmegen ultra-sensitive Bethesda Assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A","volume":"231","author":"Valke","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.103334_bib13","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.thromres.2015.08.014","article-title":"Heat treatment of samples improve the performance of the Nijmegen-Bethesda assay in hemophilia A patients undergoing immune tolerance induction","volume":"136","author":"de Lima Montalv\u00e3o","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.103334_bib14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103334_bib15","first-page":"345","article-title":"Acquired hemophilia with inhibitors presenting as an emergency: misinterpretation of clotting results during direct oral anticoagulation","volume":"111","author":"S\u00fcmnig","year":"2014","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.rpth.2025.103334_bib16","article-title":"\"Accessory after the factors\": a rare case of an acquired factor VIII inhibitor in a 75-year-old man on rivaroxaban","volume":"13","author":"Gutierrez","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.rpth.2025.103334_bib17","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s11606-020-05904-0","article-title":"Oral anticoagulant utilization in the United States and United Kingdom","volume":"35","author":"Colacci","year":"2020","journal-title":"J Gen Intern Med"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925006582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925006582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:54:13Z","timestamp":1778896453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037925006582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2475037925006582"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103334","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct oral anticoagulant interference and removal in the factor VIII inhibitor assay","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103334"}}